| 张米桥,姚 娟,李继红,张银波,李宇曦.肺力咳合剂辅助布地奈德和复方异丙托溴铵对支气管哮喘患儿肺功能、炎症介质和免疫功能的影响[J].,2023,(4):7968-800 |
| 肺力咳合剂辅助布地奈德和复方异丙托溴铵对支气管哮喘患儿肺功能、炎症介质和免疫功能的影响 |
| Effects of Feilike Heji Combined with Budesonide and Compound Ipratropium Bromide on Lung Function, Inflammatory Mediators and Immune Function in Children with Bronchial Asthma |
| 投稿时间：2022-06-30 修订日期：2022-07-26 |
| DOI：10.13241/j.cnki.pmb.2023.04.038 |
| 中文关键词: 肺力咳合剂 布地奈德 复方异丙托溴铵 支气管哮喘 肺功能 炎症介质 免疫功能 |
| 英文关键词: Feilike Heji Budesonide Compound ipratropium bromide Bronchial asthma Lung function Inflammatory mediators Immune function |
| 基金项目:湖南省中医药科研计划项目（2017774） |
|
| 摘要点击次数: 650 |
| 全文下载次数: 469 |
| 中文摘要: |
| 摘要 目的：探讨肺力咳合剂辅助布地奈德和复方异丙托溴铵对支气管哮喘患儿肺功能、炎症介质和免疫功能的影响。方法：选择2021年2月~2022年3月期间我院小儿内科接收的76例支气管哮喘患儿。根据信封抽签法将患儿分为对照组（n=38，布地奈德和复方异丙托溴铵治疗）和研究组（n=38，肺力咳合剂辅助布地奈德和复方异丙托溴铵治疗）。对比两组患儿疗效、肺功能、炎症介质和免疫功能，同时记录两组治疗期间的用药安全性状况。结果：研究组的临床总有效率较对照组明显升高（P<0.05）。治疗2周后，研究组第1秒用力呼气容积（FEV1）、用力呼气流量（PEF）、用力肺活量（FVC）高于对照组同期（P<0.05）。治疗2周后，研究组白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）低于对照组，干扰素-γ（IFN-γ）高于对照组（P<0.05）。治疗2周后，研究组CD8+低于对照组，CD3+、CD4+、CD4+/CD8+较对照组高（P<0.05）。不良反应发生率组间对比无差异（P>0.05）。结论：肺力咳合剂辅助布地奈德和复方异丙托溴铵治疗支气管哮喘患儿，可有效改善患儿的肺功能和免疫功能，降低炎症介质水平，疗效可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Feilike Heji combined with budesonide and compound ipratropium bromide on lung function, inflammatory mediators and immune function in children with bronchial asthma. Methods: 76 children with bronchial asthma who were received by the pediatric department of our hospital from February 2021 to March 2022 were selected as the observation objects. The children were divided into the control group (n=38, budesonide and compound ipratropium bromide treatment) and the study group (n=38, Feilike Heji combined with budesonide and compound ipratropium bromide treatment) by envelope lottery. The curative effect, lung function, inflammatory mediators and immune function of the two groups were compared, at the same time, the drug safety status of the two groups during treatment was recorded. Results: The total clinical effective rate in the study group was significantly higher than that in the control group (P<0.05). 2 weeks after treatment, forced expiratory volume in the first second (FEV1) , forced expiratory flow (PEF) and forced vital capacity (FVC) in the study group were higher than those in the control group (P<0.05). 2 weeks after treatment, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) in the study group were lower than those in the control group, and interferon-γ (IFN-γ) was higher than that in the control group (P<0.05). 2 weeks after treatment, CD8+ in the study group was lower than that in the control group, and CD3+, CD4+, CD4+/CD8+ were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between groups (P>0.05). Conclusion: Feilike Heji combined with budesonide and compound ipratropium bromide in the treatment of children with bronchial asthma can effectively improve the lung function and immune function of children, reduce the level of inflammatory mediators, and which has a reliable curative effect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
